Indication

In the Female:
Ovulation Induction

 

FSHâ„¢ administered IM or SC with HCG in a sequential manner, which is indicated for ovulation induction in patients who have previously received pituitary suppression.

Multi-follicular Development

During ART FSHâ„¢ administered IM in conjunction with HCG is indicated for multiple follicular developments (controlled ovarian stimulation) during ART cycles in patients who have previously received pituitary suppression.
Polycystic Ovarian Syndrome (PCOS)

Used to treat Polycystic Ovarian Syndrome (PCOS) related infertility

In the Male: Male infertility treatment in combination with HCG Induction of Spermatogenesis in men deficient spermatogenesis due to Hypogonadotrophic-hypogonadism.


Dosage & Administration

To prevent painful injections and minimize leakage from the injection site FSHâ„¢ should be slowly administered intramuscularly or subcutaneously. The subcutaneous injection site should be alternated to prevent lipoathrophy. Any unused solution should be discarded. Subcutaneous injection of FSHâ„¢ may be carried out by patient or partner, provided that proper instructions are given by the physician. Self administration of FSHâ„¢ should only be performed by patients who are well-motivated, adequately trained and with access to expert advice.
Dosage in Female

There are great inter-and intra-individual variations in the response of the ovaries to exogenous gonadotrophins. This makes it impossible to set a uniform dosage scheme. The dosage should, therefore, be adjusted individually depending on the ovarian response. This requires ultrasonography and monitoring of oestradiol levels. There should be consideration to minimize the risk of unwanted ovarian hyperstimulation. FSHâ„¢ can be given either alone, or in combination with a GnRH analogue to prevent premature luteinisation. In the latter case, especially when using a GnRH agonist, a higher total treatment dose of FSHâ„¢ may be required to achieve an adequate follicular response. Clinical experience with FSHâ„¢ is based on up to three treatment cycles in both indications. Overall experience with IVF indicates that in general the treatment success rate remains stable during the first four attempts and gradually declines thereafter.

Ovulation Induction in Women

Starting daily dose of 50 international units (IU) of FSHâ„¢ is administered subcutaneously or intramuscularly for at least the first 7 days. The dose is increased by 25 or 50 international units (IU) at weekly intervals until follicular growth and/or serum estradiol levels indicate an adequate response. When an acceptable pre-ovulatory state is achieved, final oocyte maturation is achieved with 5000 to 10,000 international units (IU) of human chorionic gonadotropin (HCG). The woman and her partner should have intercourse daily, beginning on the day prior to the administration of HCG and until ovulation becomes apparent

Assisted Reproductive Technology (ART)

In Women; Starting dose of 150 to 225 international units (IU) of FSHâ„¢ is administered intramuscularly for at least the first 4 days of treatment. Subsequent doses are adjusted based upon ovarian response as determined by ultrasound evaluation of follicular growth and serum estradiol levels. Final oocyte maturation is induced with a dose of 5000- 10,000 international units of HCG Oocyte (egg) retrieval is performed 34 to 36 hours later

Polycystic Ovarian Hyperstimulation (PCOS)

FSHâ„¢ injections are therefore given each morning as an intramuscular injection. It is best to start with the lowest dose of FSHâ„¢ per day (using 50 IU per day). These doses are used for 4 to 6 days at a time. The ovarian response is determined by measuring oestrogen levels in the blood. When the oestrogen begins to rise, the FSHâ„¢ is successfully growing an egg or eggs. If there is no response to a dose of FSHâ„¢ in 5- 6 days of injections the dose will be increased. The normal dose increments are 75 units, 112 units, 150 units and 225 units per day. Most patients respond with 75 to 150 IU per day. However it is very important that increments are only made cautiously.

 

Dosage in Male
Induction of Spermatogenesis in Men
Pre-treatment with HCG alone (1500 international units (IU) twice weekly) is required. If serum testosterone levels have not normalized after 8 weeks of HCG treatment, the dose may be increased to 3000 international units (IU) twice a week. After normalization of serum testosterone levels, administer 450 international units (IU) per week (225 international units twice weekly or 150 international units (IU) three times weekly) of FSHâ„¢ subcutaneously with the same pre-treatment HCG dose used to normalize testosterone level.
Reconstitution
To prepare the solution, inject 1 ml of sterile saline for injection into the vial of 75 IU
FSHâ„¢. Do not shake, but gently swirl until the solution is clear. Generally FSHâ„¢ dissolves
immediately. Check the liquid in the container; if it is not clear or contains particles, do not
use it. For patients requiring a single injection from multiple vials of FSHâ„¢ up to 4 vials
can be reconstituted with 1 ml of sterile saline for injection. This can be accomplished by
reconstituting a single vial as described above. Then draw the entire contents of the first
vial into a syringe and inject the contents into a second vial of lyophilized Urofollitropin.
Gently swirl the second vial, once again checking to make sure the solution is clear and
free of particles. This step can be repeated with 2 additional vials for a total up to 4 vials
(300 IU) of 75 IU FSHâ„¢


Precautions

The presence of uncontrolled non gonodalendocrinopathies (e.g. thyroid, adrenal or
pituitary disorders) should be excluded

  • In pregnancies occurring after induction of ovulation with gonadotrophin preparations, there is an increased risk of multiple gestations (Multiple birth)
  • There has been no reports of hypersensitivity to FSHâ„¢, but there remains the possibility of anaphylactic responses
  • The first injection of FSHâ„¢ should be performed under direct medical supervision
  • Since infertile women undergoing assisted reproduction, and particularly IVF, often have tubal abnormalities the incidence of ectopic pregnancies might be increased. Early ultrasound confirmation that a pregnancy is intrauterine is therefore important.
  • Rates of pregnancy loss in women undergoing assisted reproduction techniques are higher than in the normal population.
  • Unwanted ovarian hyperstimulation in the treatment of female patients, ultrasonographic assessment of follicular development, and determination of oestradiol levels should be performed prior to treatment and at regular intervals during treatment. Apart from the development of a high number of follicles, oestradiol levels may rise very rapidly, e.g. more than a daily doubling for two or three consecutive days, and possibly reaching excessively high values. The diagnosis of ovarian hyperstimulation may be confirmed by ultrasound examination. If this unwanted ovarian hyperstimulation occurs (i.e. not as part of controlled ovarian hyperstimulation in medically assisted reproduction programs), the administration of FSHâ„¢ should be discontinued. In that case pregnancy should be avoided and HCG must be withheld, because it may induce, in addition to multiple ovulation, the ovarian hyperstimulation syndrome (OHSS).
  • In men, semen analysis is recommended 4 to 6 months after the beginning of treatment in assessing the response

Pregnancy and lactation
Category: X (FSH must not be used during pregnancy and lactation).


Product Details


Related Products

Medroxy

Medroxy Progesterone Acetate
Hormone

Leroxy

Levothyroxine Sodium
Hormone

Tibo

Tibolone
Hormone

Remens

Norethisterone
Hormone

Allynol

Allylestrenol
Hormone